Exhibit 99.1

NEWS RELEASE for November 28, 2005
Contact:   Dina L. Masi, CFO
           Integrated BioPharma, Inc.
           888-319-6962
           d.masi@ibiopharma.com


            Integrated BioPharma Announces Senior Management Changes

HILLSIDE,  N.J., November 28, -- Integrated  BioPharma,  Inc announced today the
appointment  of Ms. Dina L. Masi as the Company's  Chief  Financial  Officer and
Senior Vice  President.  Mr. Eric Friedman,  who was the acting Chief  Financial
Officer,  will be dedicating his time to his duties and  responsibilities as the
Chief Executive Officer of AgroLabs, Inc., a wholly-owned subsidiary of INB.

"We are very pleased that Ms. Masi has joined INB," said E. Gerald Kay, CEO and
Chairman of the Board. "Dina is a highly accomplished financial executive with
over twenty years of financial, accounting, business development and strategic
planning skills. We were fortunate to have Mr. Friedman cover the CFO position
while we conducted our search and are grateful for the dedication he has given
to the Company."

Ms. Masi most recently operated a financial services consulting firm providing
accounting and financial services to small business owners. Ms. Masi also served
as a consultant to SEC registrants. Prior to that, Ms. Masi served as the Chief
Financial Officer of a mortgage finance company and a Senior Vice President and
Management Information Officer of a financial consulting services company.
Before that, Ms. Masi served as the Chief Financial Officer of The Aegis
Consumer Funding Group, Inc., a publicly traded consumer finance company
specializing in automobile receivables. Ms. Masi began her career as an auditor
with BDO Seidman, LLP.

Ms. Masi earned a Bachelors of Business Administration from St. Bonaventure
University, St. Bonaventure, New York. She is a Certified Public Accountant.

About Integrated BioPharma Inc (INB)

     Integrated BioPharma is a unique grouping of companies presently serving
the varied needs of the health care industry. Through its nutraceutical
business, the Company creates, develops, manufactures and markets products
worldwide. The Company's biotechnology business uses its patented plant-based
technology to produce vaccines and therapeutic antibodies. Its pharmaceutical
business operates a cGMP facility for the production and sale of Paclitaxel and
related drugs and provides technical services through its contract research
organization. Further information is available at www.iBioPharma.com.

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential risk factors that could
affect the company's financial results can be found in the company's Reports
filed with the Securities and Exchange Commission.